Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS46000468BKPyvENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30001116HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30016067HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30004832HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30014260HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30008161HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30017257HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30016998HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30019395HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TVIS30019405HIVENSG00000100385.15protein_codingIL2RBNoNo3560P14784
TCGA Plot Options
Drug Information
GeneIL2RB
DrugBank IDDB00004
Drug NameDenileukin diftitox
Target IDBE0000651
UniProt IDP14784
Regulation Typeagonist
PubMed IDs15811959; 16516670; 18684057; 17187516; 11752352
CitationsFoss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.@@Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.@@Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.@@Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKBPA164750594
ChEMBLCHEMBL1201550